Aspira Women's Health signs 5-year lab services pact with Mayo Clinic

Aspira Women's Health Inc.

Aspira will provide Ova1Plus and OvaWatch tests to Mayo on a non-exclusive, as-requested basis for clinical purposes.
Initial term of 5 years, automatic annual renewals; either party may terminate with 90 days' notice.
Mayo to list tests in its catalog, handle ordering, results delivery, and billing; Aspira invoices Mayo.
Fees fixed during initial term absent mutual adjustment; agreement not yet filed due to redactions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Aspira Women's Health Inc. entered into Laboratory Services Agreement with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (effective 2025-12-16).

Action: entry
Agreement: supply
Counterparty: Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories
Effective: 2025-12-16

Exact text from the filing

On December 16, 2025, Aspira Women’s Health Inc. (“Aspira”) entered into a Laboratory Services Agreement (the “Agreement”) with Mayo Collaborative Services, Inc., d/b/a Mayo Clinic Laboratories (“Mayo”).

View on SEC.gov

85 material agreements filed in the last 30 days. Browse all material agreements →

Aspira Women's Health Inc. filing history →

Source: SEC EDGAR

accession 0000926617-25-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.